CDKN2A and chordoma: This hypothesis is reinforced by genetic analyses performed on the CD7 chordoma PDX model, which confirmed the loss of CDKN2A/2B in treated and control mice, but not in the primary patient’s tumor (35), suggesting a spatial tumor heterogeneity in which some cells harbor the homozygous deletion of CDKN2A, and others do not.